Detailed antibody characterization is a critical component of the discovery process for therapeutic monoclonal antibodies (MAbs). Epitope data informs mechanism-of-action and lead candidate selection, and is valuable for obtaining MAb patent protection. Detailed antibody specificity analysis is crucial for predicting clinical safety by identifying off-target interactions, thereby de-risking antibody therapeutic development.
Integral Molecular has developed innovative solutions such as Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array for characterizing antibodies against cell surface targets. These assays are run on Intellicyt’s sensitive, high-throughput flow cytometry platform to detect MAb binding to proteins natively expressed on cells.
- How epitope mapping data can elevate the value of monoclonal antibodies through mechanism-of-action insights and enhanced intellectual property
- Case studies demonstrating how detailed specificity analysis can reveal off-target antibody interactions, and de-orphan antibodies obtained through functional screening
- How Intellicyt’s platform provides reproducible generation of high-throughput data, enabling the high success rate of Epitope Mapping and Membrane Proteome Array technologies
Rachel Fong, Project Leader, Epitope Mapping, Integral Molecular
Duncan Huston-Paterson, D Phil, Project Leader, Membrane Proteome Array, Integral Molecular